Ultra-low-pass whole-genome sequencing (ULP-WGS) of circulating tumor DNA (ctDNA) can provide clinically relevant information about tumor biology in patients with hepatocellular carcinoma (HCC) under systemic treatment. The presence of ctDNA and the loss of specific genomic regions (5q and 16q) were identified as independent predictors of worse prognosis in advanced HCC patients receiving systemic therapy. These findings highlight the potential of ULP-WGS in identifying patients with HCC who carry a worse prognosis.
Journal Article by Sogbe M, Bilbao I (…) Sangro B et 9 al. in Clin Mol Hepatol